Belgian biopharmaceutical company UCB announced on Monday the construction of a new research and development centre on its campus in Braine-l'Alleud (Walloon Brabant).
The project, named Arkelia, will focus on research in neurodegeneration, neuroinflammation and epilepsy.
This new site will be connected to the gene therapy pharmaceutical development centre, currently in its final phase of construction, and to the neurology research facilities.
Some 170 employees will work there. It is currently scheduled to open in mid-2028.
"This investment strengthens the collaboration between our research, development, manufacturing and supply activities, ensuring optimal coordination during critical phases to accelerate progress, while maintaining flexibility and reducing environmental impact," commented Myriam Juckler, head of UCB's Braine-l'Alleud campus.
In April, the company inaugurated a new bio-manufacturing operations centre, which represented a previous investment of €300 million.
